相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Camrelizumab: an investigational agent for hepatocellular carcinoma
Bin Xu et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2022)
Irinotecan and vandetanib create synergies for treatment of pancreatic cancer patients with concomitant TP53 and KRAS mutations
Aman Chandra Kaushik et al.
BRIEFINGS IN BIOINFORMATICS (2021)
Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinoma
Dingwei Ye et al.
CANCER SCIENCE (2021)
Toripalimab with nab-paclitaxel/gemcitabine as first-line treatment for advanced pancreatic adenocarcinoma: Updated results of a single-arm, open-label, phase Ib/II clinical study.
Ke Cheng et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
Yelena Y. Janjigian et al.
LANCET (2021)
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial
Thomas Powles et al.
LANCET ONCOLOGY (2021)
Pancreatic Adenocarcinoma, Version 2.2021
Margaret A. Tempero et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)
Pembrolizumab for advanced anal squamous cell carcinoma (ASCC): Results from the multicohort, phase II KEYNOTE-158 study
Aurelien Marabelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
The efficacy and toxicity of chemotherapy in the elderly with advanced pancreatic cancer
Xiang Li et al.
PANCREATOLOGY (2020)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer
Louis Buscail et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2020)
Pseudoprogression and Hyperprogression as New Forms of Response to Immunotherapy
Maxime Frelaut et al.
BIODRUGS (2020)
Cancer immunotherapy: Pros, cons and beyond
Shuzhen Tan et al.
BIOMEDICINE & PHARMACOTHERAPY (2020)
Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial
Feng Wang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer
Zev A. Wainberg et al.
CLINICAL CANCER RESEARCH (2020)
Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study
Lin Shen et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
The Immune Microenvironment in Pancreatic Cancer
Magdalena Huber et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Effectiveness and safety of toripalimab, camrelizumab, and sintilimab in a real-world cohort of hepatitis B virus associated hepatocellular carcinoma patients
Jinzhang Chen et al.
ANNALS OF TRANSLATIONAL MEDICINE (2020)
Sintilimab: A Promising Anti-Tumor PD-1 Antibody
Lin Zhang et al.
FRONTIERS IN ONCOLOGY (2020)
KRAS G12C mutations in Asia: a landscape analysis of 11,951 Chinese tumor samples
Herbert Ho-Fung Loong et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2020)
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
Aurelien Marabelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Dendritic cells in cancer immunology and immunotherapy
Stefanie K. Wculek et al.
NATURE REVIEWS IMMUNOLOGY (2020)
ARF6 and AMAP1 are major targets of KRAS and TP53 mutations to promote invasion, PD-L1 dynamics, and immune evasion of pancreatic cancer
Shigeru Hashimoto et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
P. Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma
Zhong-Yi Dong et al.
CLINICAL CANCER RESEARCH (2017)
5-FU resistant EMT-like pancreatic cancer cells are hypersensitive to photochemical internalization of the novel endoglin-targeting immunotoxin CD105-saporin
Kaja Lund et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2017)
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le et al.
SCIENCE (2017)
PD-1/PD-L1 and immunotherapy for pancreatic cancer
Mengyu Feng et al.
CANCER LETTERS (2017)
A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus)
Glen J. Weiss et al.
BRITISH JOURNAL OF CANCER (2017)
Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities
Barbara Bournet et al.
EUROPEAN JOURNAL OF CANCER (2016)
Genomic analyses identify molecular subtypes of pancreatic cancer
Peter Bailey et al.
NATURE (2016)
KRAS-related proteins in pancreatic cancer
Karen M. Mann et al.
PHARMACOLOGY & THERAPEUTICS (2016)
Antagonists of PD-1 and PD-L1 in Cancer Treatment
Evan J. Lipson et al.
SEMINARS IN ONCOLOGY (2015)
Tumor-infiltrating dendritic cells exhibit defective cross-presentation of tumor antigens, but is reversed by chemotherapy
Alison M. McDonnell et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2015)
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Daniel D. Von Hoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Murine Melanoma-Infiltrating Dendritic Cells Are Defective in Antigen Presenting Function Regardless of the Presence of CD4+CD25+ Regulatory T Cells
Haley Ataera et al.
PLOS ONE (2011)
分享论文
